<SEC-DOCUMENT>0001161697-20-000491.txt : 20201117
<SEC-HEADER>0001161697-20-000491.hdr.sgml : 20201117
<ACCEPTANCE-DATETIME>20201116174856
ACCESSION NUMBER:		0001161697-20-000491
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201116
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201117
DATE AS OF CHANGE:		20201116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPRO MED SYSTEMS INC
		CENTRAL INDEX KEY:			0000704440
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133044880
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39086
		FILM NUMBER:		201318682

	BUSINESS ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
		BUSINESS PHONE:		845-469-2042

	MAIL ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form_8-k.htm
<DESCRIPTION>FORM 8-K CURRENT REPORT FOR 11-16-2020
<TEXT>
<HTML>
<HEAD>
</HEAD>
<TITLE></TITLE>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<DIV style="width:7.5in">
<BR>
<P style="margin:0" align=center><B>UNITED STATES</B></P>
<P style="margin:0" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0" align=center><B>Washington, DC 20549</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>FORM 8-K</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>CURRENT REPORT</B></P>
<P style="margin:0; font-size:12pt" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center>Date of Report (Date of earliest event reported)&nbsp;&nbsp;&nbsp;<B><U>November 16, 2020</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:14pt" align=center><B><U>REPRO MED SYSTEMS, INC.</U></B></P>
<P style="margin:0" align=center>(Exact name of registrant as specified in its charter)</P>
<P style="margin:0" align=center>&nbsp;</P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>0-12305</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>13-3044880</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(State or other jurisdiction<BR>
of incorporation)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(Commission<BR>
File Number)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(IRS Employer<BR>
Identification No.)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center><B><U>24 Carpenter Road, Chester, New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center><B><U>10918</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center>(Address of principal executive offices)</P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center>(Zip Code)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<P style="margin:0" align=center>Registrant&rsquo;s telephone number, including area code&nbsp;&nbsp;&nbsp;<B><U>(845) 469-2042</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center><U>not applicable</U></P>
<P style="margin:0" align=center>(Former name or former address, if changed since last report)</P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Securities registered pursuant to Section 12(b) of the Act:</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-top: 0px; font-size: 10pt"><TR height=0 style="font-size:1pt"><TD STYLE="width: 2.5in"></TD><TD STYLE="width: 2.5in"></TD><TD STYLE="width: 2.5in"></TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Title of each class</U></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Trading symbol(s)</U></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Name of each exchange on which registered</U></P>
</TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">Common stock, $0.01 par value</P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">KRMD</P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">The Nasdaq Stock Market</P>
</TD></TR>
</TABLE>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P STYLE="margin: 0 0 0 5.3in; text-align: justify">Emerging growth company &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0"><B>ITEM 8.01 OTHER EVENTS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">On November 16, 2020, the Board of Directors (the &ldquo;Board&rdquo;) of Repro Med Systems, Inc. d/b/a KORU
Medical Systems (the &ldquo;Company&rdquo;) authorized and approved a stock repurchase program for up to $10 million of the currently
outstanding shares of the Company&rsquo;s common stock through December 31, 2021. Under the stock repurchase program, the Company
may repurchase shares in open market transactions at prevailing market prices, in privately negotiated transactions, or by other
means in accordance with applicable federal securities laws, including Rule 10b-18 of the Securities Exchange Act of 1934 (the
&ldquo;Exchange Act&rdquo;). Purchases pursuant to the stock repurchase program will be at times and in amounts as determined appropriate
by the Company and will depend on a number of factors, including price and general business and market conditions. The stock repurchase
program replaces the Company&rsquo;s previous stock repurchase program, which had been discontinued by management in June 2017.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0"><B>ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-align: justify">(d) Exhibits.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 720px">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 96"><U>Exhibit No.</U></TD>
    <TD STYLE="width: 624"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>99.1</TD>
    <TD><A HREF="ex_99-1.htm">Press release dated November 16, 2020</A></TD></TR>
</TABLE>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify"><BR></P>

<P style="margin:0" align=center><B>SIGNATURES</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-indent:0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 width=100%>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=360 colspan=2><P style="margin:0">REPRO MED SYSTEMS, INC.<BR>
(Registrant)</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">&nbsp;</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">Date: &nbsp;<U>November 16, 2020</U></P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">By:</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0"><U>/s/ Karen Fisher</U></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top colspan=2><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">Karen Fisher<BR>
Chief Financial Officer</P>
</TD></TR>
</TABLE>
<P style="margin:0"><BR></P>
<P style="margin:0" align=center>- 2 -</P>
<HR noshade align="center" width="100%" size="2">
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex_99-1.htm
<DESCRIPTION>PRESS RELEASE DATED NOVEMBER 16, 2020
<TEXT>
<HTML>
<HEAD>
</HEAD>
<TITLE></TITLE>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<DIV style="width:7.5in">
<BR>
<P style="margin:0px" align=center><B>Exhibit 99.1</B></P>
<P style="margin:0px"><img src="koru_logo.jpg" align=middle></P>
<P style="margin:0px" align=center><B><U>FOR IMMEDIATE RELEASE</U></B></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><B><U>KORU MEDICAL SYSTEMS ANNOUNCES STOCK REPURCHASE PROGRAM</U></B></P>
<P style="margin:0px" align=center><BR></P>

<P style="margin:0px; text-align: justify"><B>CHESTER, NY &ndash; November 16, 2020 &ndash; Repro Med Systems, Inc. dba KORU
Medical Systems (NASDAQ: KRMD) (&ldquo;KORU Medical&rdquo; or the &ldquo;Company&rdquo;)</B> today announced that its Board
of Directors has authorized a stock repurchase program under which the Company may purchase up to $10 million of its
outstanding common stock through December 31, 2021.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">&ldquo;We believe that this repurchase program demonstrates confidence in our
long-term outlook, the underlying value of KORU Medical stock, and our commitment to maximizing value for our
shareholders,&rdquo; said Don Pettigrew, Chief Executive Officer. &ldquo;Our strong balance sheet enables us to support this
repurchase plan, while continuing to invest in our operations and explore investments that generate long-term
growth.&rdquo;</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">Chairman of the Board John Fletcher commented, &ldquo;We are committed to
enhancing shareholder value.&nbsp; This authorization reflects the Board&rsquo;s continued confidence in the Company&rsquo;s
long-term growth prospects, the value of KORU Medical&rsquo;s Freedom Integrated Infusion System, and the significant
expansion opportunities that exist both within and adjacent to our core business.&rdquo;</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">The shares may be repurchased periodically in open market transactions at
prevailing market prices, in privately negotiated transactions, or by other means in accordance with federal securities laws.
The actual timing and amount of shares repurchased under the program will be determined by the Company in its discretion and
will depend on a number of factors, including price, general business and market conditions, and applicable legal
requirements. The repurchase plan will be funded using cash on hand.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify"><B><U>About KORU Medical Systems</U></B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">KORU Medical Systems develops, manufactures, and commercializes innovative and
easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe
Infusion System currently includes the FREEDOM60<SUP>&reg;</SUP> and FreedomEdge<SUP>&reg;</SUP> Syringe Infusion Drivers,
Precision Flow Rate Tubing<SUP>&trade;</SUP> and HIgH-Flo Subcutaneous Safety Needle Sets<SUP>&trade;</SUP>. These devices
are used for infusions administered in the home and alternate care settings. For more information, please visit
www.korumedical.com.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify"><B><U>Forward-looking Statements</U></B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">This press release contains forward-looking statements that involve risks and
uncertainties. Forward-looking statements can be identified by words such as &ldquo;may,&rdquo; &ldquo;believe&rdquo; and
&ldquo;enables.&rdquo; Actual results may differ materially from the results predicted and reported results should not be
considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to
differ from the results predicted include, among others, uncertainties associated with COVID-19, future operating results,
availability of investment opportunities, market fluctuations, and those risks and uncertainties included under the captions
&ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2019, and our Quarterly Report
on Form 10-Q for the quarter ended September 30, 2020, which are on file with the SEC and are available on our website at
www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in the
attachments is as of November 13, 2020. Undue reliance should not be placed on the forward-looking statements in this press
release, which are based on information available to us on the date hereof. We undertake no duty to update this information
unless required by law.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px"><B>Contacts:</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><B>The Equity Group Inc.</B></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:1pt"><TD width=237.867 ></TD><TD width=194.133 ></TD></TR>
<TR><TD style="margin-top:0px" valign=top width=237.867><P style="margin:0px">Devin Sullivan</P>
</TD><TD style="margin-top:0px" valign=top width=194.133><P style="margin:0px">Kalle Ahl, CFA</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=237.867><P style="margin:0px">Senior Vice President</P>
</TD><TD style="margin-top:0px" valign=top width=194.133><P style="margin:0px">Vice President</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=237.867><P style="margin:0px">212-836-9608</P>
</TD><TD style="margin-top:0px" valign=top width=194.133><P style="margin:0px">212-836-9614</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=237.867><P style="margin:0px">dsullivan@equityny.com</P>
</TD><TD style="margin-top:0px" valign=top width=194.133><P style="margin:0px">kahl@equityny.com</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>

<HR noshade align="center" width="100%" size="2">
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>koru_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 koru_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  \ , # 2(  A$! Q$!_\0
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M!\5/"T[O^#N]BO\ P42^!K+PR?L2^#&4]>5^.7Q_(_45\+_MC_\ !/GX^_\
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M&SX=[W_@T\_:M\2?&/\ 8?\ B;^S=XQU:?6-1_9%^)MEH_@::Y9IKC3O@O\
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M9_M/7EU,Q Q'%\%/&QV1J2/,GF;;#;PKF2>>2.&-6DD52 ?Q'?\ !H7_ ,I
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D$/ACXH^,^O\ C[Q'X!\!+JFCZ+J(UWQO\3/%'CG[:HHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
